Martin F. Dietrich, MD, assistant professor of internal medicine at the University of Central Florida College of Medicine and ...

T-DXd plus pertuzumab improved quality-of-life outcomes, with fewer skin and mucosal symptoms but more gastrointestinal issues compared to the standard regimen. Both treatment arms showed similar pain ...

The ACCESS trial shows mismatched unrelated donors can provide excellent outcomes, addressing racial disparities in donor ...

Panelists discuss how real-world practice often diverges from guideline recommendations due to access barriers, toxicity ...

Panelists discuss how the next generation of targeted agents, including sunvozertinib, BLU-945, and antibody-drug conjugates, ...

Quality of life emerges as a central theme, with panelists emphasizing that patient-reported outcomes and psychosocial ...

Thoughtful sequencing not only maximizes overall survival but also minimizes unnecessary toxicity. Planning enables ...

The TKI plus InO-based therapy for newly diagnosed Ph+ ALL successfully met the efficacy end point, achieving an 81% MR3+ rate within 2 courses with limited cycles of InO. The modified schema 2 ...

Aromatase inhibitors demonstrated superior disease-free survival and time to distant recurrence compared to SERMs in HR+/HER2+ early breast cancer. The benefits of aromatase inhibitors were consistent ...

Giredestrant significantly improved IDFS in ER-positive, HER2-negative early breast cancer, reducing recurrence or death risk by 30% compared to SOC endocrine therapy. Subgroup analyses showed ...

The combination of talquetamab-tgvs and pomalidomide achieved an 85.7% objective response rate in relapsed/refractory multiple myeloma patients. Median progression-free survival was 25.8 months, with ...

During a live event, Yelena Y. Janjigian, MD, moderated a discussion on how to use PD-L1 CPS status when considering ...